Related Experiment Videos
Depot fluspirilene for schizophrenia
1Department of Psychological Medicine, Guy's, King's and St. Thomas' College School of Medicine, 103 Denmark Hill, London, UK, SE5 8AF. spjuasd@iop.kcl.ac.uk
The Cochrane Database of Systematic Reviews
|May 5, 2000
Summary
Current evidence does not support depot fluspirilene over oral antipsychotics or other depot preparations for schizophrenia. More high-quality trials are needed to determine its efficacy and advantages.
Area of Science:
- Psychiatry and Pharmacology
- Clinical Trial Analysis
Background:
- Antipsychotic medications are standard treatments for schizophrenia.
- Long-acting injectable antipsychotics, like fluspirilene, are used for maintenance therapy.
Purpose of the Study:
- To evaluate depot fluspirilene against placebo, oral antipsychotics, and other depot preparations.
- To assess clinical, social, and economic outcomes in schizophrenia patients.
Main Methods:
- Systematic review of randomized controlled trials (RCTs) identified through extensive database searches (Biological Abstracts, Cochrane Library, EMBASE, MEDLINE, PsycLIT).
- Included trials compared depot fluspirilene with oral antipsychotics or other depot formulations.
- Outcomes analyzed included mortality, global function, mental state, relapse, hospitalization, adverse effects, and treatment acceptability.
Main Results:
- Seven studies were included, most with small participant numbers.
- No significant advantages of depot fluspirilene were found compared to oral chlorpromazine or other depot antipsychotics.
- Hospital, service, patient satisfaction, and economic outcomes were not reported in the included studies.
Conclusions:
- Limited data from small trials show no clear differences between fluspirilene and other treatments.
- Current trial data cannot inform the use or advantages of depot fluspirilene over other depot antipsychotics.
- Well-designed and reported RCTs are necessary to guide clinical practice regarding fluspirilene.